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Hyperlipidemia, diabetes mellitus type 2, and coronary heart
disease have been associated with being born small for ges-
tational age (SGA). It has been reported that GH treatment
induced higher insulin levels, which has led to concern re-
garding the long-term effect of GH treatment in predisposed
individuals such as children born SGA. In this study, we as-
sessed the effect of discontinuation of long-term GH treatment
in 47 adolescents born SGA on oral glucose tolerance tests,
blood pressure (BP), and serum lipid levels for two GH dosage
groups (3 vs. 6 IU/m2d). At 6 months after discontinuation of
GH treatment mean (SD) age was 16.0 (2.1) yr. Mean duration
of GH treatment had been 6.9 (1.5) yr. Fasting glucose levels
and 120-min area under the curve for glucose 6 months after
discontinuation of GH treatment showed no difference from
pretreatment levels for both GH dosage groups. After discon-
tinuation of GH treatment, fasting insulin levels returned to
pretreatment levels (8.4 mU/liter), whereas the 120-min area
under the curve for insulin decreased, compared with 6-yr
levels (P < 0.01), regardless of GH dosage group. No signifi-
cant difference was found when levels were compared with
a control group. In addition, for both GH dosage groups, no
significant changes in systolic and diastolic BP SD score,
total cholesterol, and atherogenic index (total cholesterol/
high-density lipoprotein cholesterol) were seen from 6 yr of
GH until 6 months after discontinuation of GH treatment. In
conclusion, in children born SGA, the GH-induced insulin
insensitivity disappeared after discontinuation of GH, even
after long-term GH treatment. Furthermore, the beneficial
effect of GH on BP was not changed after discontinuation
of GH, and most children had normal lipid levels. (J Clin
Endocrinol Metab 88: 347–353, 2003)
SINCE THE FIRST reports of correlation between lowbirth weight (LBW) and high blood pressure (BP) in the
1980s (1), a large number of studies have elaborated on the
consequences of LBW in relation to adult disease. Several
other diseases such as hyperlipidemia, diabetes mellitus
(DM) type 2, and coronary heart disease have also been
associated with LBW (2, 3). Based on his findings, Barker (4)
suggested that the associated adult diseases, so-called syn-
drome X, are programed by undernutrition in utero. Impaired
fetal growth, especially when timed during the mid- to late
gestation, would lead to permanent changes in organ struc-
ture and physiology.
Failure to show sufficient catch-up growth in childhood is
a known phenomenon in about 10–15% of children born
small for gestational age (SGA) (5, 6). Several studies (7, 8)
have shown accelerated growth during GH treatment. How-
ever, it has been established that GH treatment increases
postprandial insulin levels, probably because of a reduction
in insulin sensitivity (9). This finding has instigated several
authors to express their concern regarding long-term effects
of GH treatment in predisposed individuals such as SGA
children (10).
We previously reported on the effect of 6 yr of GH treat-
ment on carbohydrate metabolism, BP, and serum lipid lev-
els in children born SGA (11, 12). The present article focuses
on the effect of discontinuation of long-term GH treatment
on carbohydrate metabolism, BP, and serum lipid levels in
children born SGA.
Subjects and Methods
Study group
The study group comprised 47 children born SGA who were exam-
ined 6 months after discontinuation of GH treatment. Thirty children
had an oral glucose tolerance test (OGTT) 6 months after discontinuation
of GH. They had participated in a multicenter, double-blind, random-
ized, dose-response GH trial in prepubertal short children born SGA.
Four children who had discontinued GH treatment did not agree to an
examination 6 months after discontinuation of GH treatment and 28
were still receiving GH treatment.
The ongoing dose-response trial evaluates the effect of two dosages
of GH (3 or 6 IU GH/m2 BSA/day; approximately 0.03 or 0.07 mg/kg
body weight/day) on long-term growth and ultimately on final height.
Inclusion criteria for the dose-response trial were described previ-
ously (7). In short, the children were included when prepubertal with a
birth length sd score and height sd score below 1.88, without spon-
taneous catch-up growth and without growth failure caused by other
disorders. Patients with Silver-Russell syndrome and GH deficiency
Abbreviations: 30-min ratio, Ratio of insulin to glucose at 30 min;
120-min ratio, ratio of insulin to glucose at 120 min; AUC, area under the
curve for time concentration; BMI, body mass index; BP, blood pressure;
CA, chronological age; CV, coefficient of variation; DM, diabetes mel-
litus; FH, full height; GHD, GH deficiency; HbA1c, hemoglobin A1c;
HDL-c, high-density lipoprotein cholesterol; IGT, impaired glucose tol-
erance; LBW, low birth weight; LDL-c, low-density lipoprotein choles-
terol; OGTT, oral glucose tolerance test; SGA, small for gestational age;
TC, total serum cholesterol.
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(GHD), however, were included in this dose-response trial. The Ethics
Committees of the four participating centers in The Netherlands ap-
proved the dose-response trial. Written informed consent was obtained
from the parents or custodians of each child.
Dose-response trial design
After stratification for chronological age (CA) and for spontaneous
GH secretion during a 24-h GH profile, all children were randomly and
blindly assigned to either one of two GH dosage groups: group A, 3
IU/m2 body surface/day, or group B, 6 IU/m2 body surface/day (0.03
or 0.07 mg/kgd, respectively) (7, 13). Biosynthetic GH (recombinant
human GH Norditropin; Novo Nordisk A/S, Bagsvaerd, Denmark) was
given sc once daily. To ensure the double-blind design, an equal volume
of a reconstituted preparation was used. GH treatment was discontinued
after either reaching final height, defined as a height velocity less than
0.5 cm over the last 6 months and/or bone age 15 yr or more for girls
and 16.5 yr or more for boys, or on the decision of the patient because
of satisfaction with near final height.
Physical examination
Every 3 months one physician (1991–1995, W.d.W.; 1995–1998, T.S.;
1998–2001, Y.v.P.) visited all children and measured height (14) and
weight. Height was expressed as sd score for chronological age (CA)
(height sd score) (15). Body mass index (BMI) was expressed as sd score
for sex and CA using Dutch references (15). Every 6 months BP was
measured. Systolic and diastolic BP were determined by the same Dy-
namap Critikon 1846SX (Southern Medical Corp.) with the children in
sitting position using a cuff size corresponding to the size of their arm.
BP was expressed as sd score, using age- and sex-specific reference
values (16). Pubertal stage was assessed by the same investigators
according to Tanner (17), using an orchidometer in boys.
Biochemical parameters
At the start, after 1 and 6 years of GH treatment, all children under-
went an OGTT as previously described by Sas et al. (11). For the present
study, we performed an OGTT 6 months after GH treatment in three of
the four participating centers. To evaluate the overall responses to the
oral glucose load, the following variables were described: 1) Impaired
glucose tolerance (IGT) was defined according to the Expert Committee
on the Diagnosis and Classification of Diabetes Mellitus (18): the 120-min
level greater than 7.8 mmol/liter (140 mg/dl) and less than 11.1 mmol/
liter (200 mg/dl); 2) the 120-min area under the curve for time concen-
tration (AUC) during the OGTT was calculated using the trapezoidal
rule; and 3) the ratio insulin to glucose at 30 min (30-min ratio) and the
ratio at 120 min (120-min ratio) was calculated as an index for relative
insulin resistance. Results were compared with the data of 24 normal
adolescent girls aged 14.7 (0.98) yr and body mass index (BMI) 20.5
(2.0) kg/m2, selected on the basis of postpubertal stage (Tanner breast
stage V) as described by Potau et al. (19) (control group).
At start, during the dose-response trial and at 6 months after dis-
continuation of GH treatment, additional nonfasting blood samples
were taken for determination of hemoglobin A1c (HbA1c) levels, total
serum cholesterol (TC), low-density lipoprotein cholesterol (LDL-c),
high-density lipoprotein cholesterol (HDL-c). The atherogenic index
was calculated as the ratio of TC to HDL-c. After centrifugation, all
samples were frozen (20 C) until assayed. Serum TC, LDL-c, HDL-c
levels, and atherogenic index were compared with a Dutch control
group of the same age (20).
Assays
The plasma glucose level was measured at the local hospital labo-
ratories with automatic analyzers using a hexokinase-catalyzed glucose
oxidase method. Plasma insulin was determined in one laboratory by
RIA (Medgenix, Fleurus, Belgium). The intraassay coefficient of varia-
tion (CV) was 6–10% and the interassay CV was 6–11%. Fasting normal
range was less than 20 mU/liter. Control samples were measured
by a RIA, comparable with the RIA we used (R2  0.988; y  0.397 
0.925  x) (19).
HbA1c levels were measured in one laboratory using an automatic
HPLC analyzer (DIAMAT; Bio-Rad Laboratories, Inc., Edgemont, CA).
The upper-normal assay limit is 6.6%.
The TC level was measured using an automated enzymatic method
(21) with the CHOD-PAP high performance reagent kit (Boehringer,
Mannheim, Germany). TC analysis was subject to the quality assessment
program of the World Health Organization Regional Lipid Reference
Center (Prague, Czech Republic). HDL-c and LDL-c were measured by
the same method after precipitation. For HDL-c, the phosphotungstate
method of Burstein was modified (22). LDL-c precipitation was per-
formed with polyvinyl sulfate (Boehringer). The overall CV for TC,
HDL-c, and LDL-c was 2.9%, 3.7%, and 5.8%, respectively. Lipid levels
for the control group were measured by the same assays in the same
laboratory (20). Except for plasma glucose, all determinations were
performed in the same laboratories.
Statistical analyses
To maintain the double-blind design until all participants reached
final height, an independent statistician (P.M.) performed the statistical
analyses and summarized the results per treatment group in such a way
that it was impossible for the investigator to identify individual patients.
Accordingly, data are expressed as mean (sd) values unless otherwise
specified. For the 30-min ratio, the 120-min ratio, and the atherogenic
index, the geometric mean (95% range: the back-transformed  2 sd
range of the log transformed variable) was used because of the positively
skewed distributions involved. Differences in continuous variables were
tested by paired Student’s t tests. Differences between zero and sd score
values at various time points during the study were tested by one-
sample Student’s t tests. Differences between groups were tested using
a two-sample Student’s t test unless otherwise specified. Correlations
were estimated after adjustment for GH dosage. A P value less than 0.05
was considered significant. All calculations were performed using SPSS
version 9.0 (SPSS, Inc., Chicago, IL).
Results
Table 1 shows the clinical data of the 47 children. Both GH
dosage groups had similar initial characteristics. Three chil-
dren had Silver-Russell syndrome. Seventeen children had
GHD at start. Mean (sd) age at 6 months after discontinuation
of GH treatment was 16.0 (2.1) yr. No significant differences
were found in clinical data and serum glucose or insulin
levels between the 30 children who underwent an OGTT at
6 months after discontinuation of GH treatment and the 17
children who did not.
Fasting glucose levels at 6 yr of GH treatment had in-
creased significantly, compared with pretreatment (P 0.05)
but returned to pretreatment level for both GH dosage
groups at 6 months after discontinuation of GH treatment
(Fig. 1). The AUC for glucose showed no change either at 6
yr of GH treatment or 6 months after discontinuation of GH
treatment. Fasting glucose levels and the AUC for glucose
were not significantly different between the GH dosage
TABLE 1. Clinical data (n  47)
Group A
(3 IU/m2d)
Group B
(6 IU/m2d)
Male/female 16/7 11/13
Gestational age (wk) 37.7 (3.1) 36.3 (4.1)
Birth length SD score 3.4 (1.4) 3.8 (1.7)
Birth weight SD score 2.3 (1.2) 2.8 (0.9)
CA (yr) at start 8.6 (1.5) 8.3 (1.9)
Height SD score at start 2.9 (0.8) 2.8 (0.6)
BMI SD score at start 0.9 (1.5) 1.0 (1.0)
GH duration 7.2 (1.2) 6.6 (1.7)
Data expressed as mean (SD).
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groups. Similarly, no significant differences were found be-
tween the GH-treated group and the control group (Fig. 2).
Fasting insulin levels had increased at 6 yr of GH treat-
ment, compared with at pretreatment (P  0.001) but re-
turned to pretreatment levels 6 months after discontinuation
of GH treatment (Fig. 1). Also, the AUC for insulin showed
a significant increase from 3349 (1643) minmU/liter before
treatment to 6157 (2368) minmU/liter at 6 yr of GH treat-
ment (P  0.001). At 6 months after discontinuation of GH
treatment, the AUC for insulin, 4645 (3641) minmU/liter,
had significantly decreased, compared with the 6-yr level
(P  0.01) but remained higher than before treatment (P 
0.05). Compared with the control group, however, the AUC
for insulin at 6 months after discontinuation of GH treatment
showed no significant difference. No significant differences
between GH dosage groups were found for change in fasting
insulin levels and AUC for insulin (Fig. 3).
The 30-min and 120-min ratios had increased significantly
at 6 yr of GH treatment, compared with pretreatment levels
(P  0.001, P  0.05, respectively). At 6 months after dis-
continuation of GH treatment, the 30-min ratio returned to
pretreatment values for group A. For group B, however, the
30-min ratio remained increased, compared with pretreat-
ment values (P 0.001). The 120-min ratio, at 6 months after
discontinuation of GH treatment, was comparable with pre-
treatment values, showing no differences between GH dos-
age groups.
After 6 yr of GH treatment, we found IGT in 1 of 27
children (4%), and at 6 months after discontinuation of GH
treatment, IGT was present in 3 of 29 children (10%). One of
the children with IGT at 6 yr of GH treatment also had IGT
at 6 months after discontinuation of GH treatment. The other
children had IGT only once during GH treatment or after
discontinuation of GH treatment. None of the children de-
veloped DM type 1 or 2.
The HbA1c values after 6 yr of GH treatment had signif-
icantly decreased from 5.1 (0.3) before treatment to 4.8 (0.4)
at 6 yr of GH treatment (P  0.001), whereas no change was
found 6 months after discontinuation of GH treatment [4.7
(0.3)]. Throughout the years, all individual HbA1c levels re-
mained within normal range.
BMI sd score after 6 yr of GH treatment had increased
FIG. 1. Mean (SD) fasting glucose levels (left) and fasting insulin levels (right) before treatment, at 6 yr of GH treatment, and at 6 months
after discontinuation of treatment for group A () and B (f), respectively.
FIG. 2. Mean glucose levels during OGTT for group A (left) and group B (right) before treatment (F), at 6 yr of GH treatment (), at 6 months
after discontinuation of treatment (‚), and for the control group ().
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significantly, compared with the pretreatment BMI sd score
of 1.0 (1.2) (P  0.001). As a result, the mean BMI sd score
of0.2 (1.1) at 6 yr was not significantly different from zero.
At 6 months after discontinuation of GH treatment, mean
BMI sd score was 0.1 (1.3), showing no significant differ-
ence, compared with 6-yr values. The change in BMI sd score
was not significantly different between GH dosage groups.
Systolic and diastolic BP decreased significantly during 6
yr of GH treatment (P  0.05, P  0.001, respectively) to
values not significantly different from zero for systolic BP
and significantly lower than zero for diastolic BP (P 0.001)
(Fig. 4). After discontinuation of GH treatment, no change in
systolic and diastolic BP was seen. The changes in BP were
not significantly different between GH dosage groups.
Serum TC, LDL-c, and HDL-c levels significantly de-
creased after 6 yr of GH treatment, compared with the start
(P  0.001 for all) (Table 2). After discontinuation of GH
treatment, TC levels showed no change, compared with 6-yr
levels for both sexes, whereas LDL-c and HDL-c levels in-
creased significantly for girls only (P  0.01, P  0.01, re-
spectively). Discontinuation of GH treatment did not result
in a change in atherogenic index, compared with 6-yr values.
Compared with the control group, serum TC, LDL-c but also
HDL-c levels were significantly lower in the GH-treated
group at 6 months after discontinuation of GH treatment,
after correction for age and gender (P  0.001, P  0.01, P 
0.01, respectively). The atherogenic index, however, was not
significantly different at 6 months after GH treatment, com-
pared with the control group (Table 2). The changes in serum
lipid levels were not significantly different between the GH
dosage groups.
A significant correlation was found between AUC for glu-
cose and AUC for insulin at 6 months after discontinuation
of GH treatment (r  0.67, P  0.0001). BMI sd score corre-
lated significantly with fasting insulin levels, systolic BP sd
score, and the atherogenic index at 6 months after discon-
tinuation of GH treatment (r  0.58 (P  0.01), r  0.32 (P 
0.05), and r 0.42, P 0.05, respectively), but no correlation
was found between BMI sd score and diastolic BP sd score
or 120-min glucose level at 6 months after discontinuation of
FIG. 3. Mean insulin levels during OGTT for group A (left) and group B (right) before treatment (F), at 6 yr of GH treatment (), at 6 months
after discontinuation of treatment (‚), and for the control group ().
FIG. 4. Mean (SD) systolic BP SD score (left) and diastolic BP SD score (right) using age-matched reference values before GH treatment, at 6 yr
of GH treatment, and at 6 months after discontinuation of treatment for group A () and group B (f).
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GH treatment. The atherogenic index at 6 months after dis-
continuation of GH treatment was also significantly corre-
lated to diastolic BP sd score (r  0.43, P  0.05) but did not
significantly correlate with systolic BP sd score, fasting in-
sulin, or 120-min glucose levels.
Regarding the change in fasting glucose, fasting insulin,
30-min ratio, 120-min ratio, or AUC for insulin from start
until 6 months after discontinuation of GH treatment, no
correlation was found with the change in BMI-sd score.
Discussion
We present the results describing the effect of discontin-
uation of long-term GH treatment on carbohydrate metab-
olism, BMI, BP, and serum lipid levels in children born SGA.
Our results showed that discontinuation of long-term GH
treatment in adolescents born SGA normalized both fasting
insulin and stimulated insulin levels after a significant in-
crease during GH treatment. Furthermore, we found that
discontinuation of GH did not alter the positive influence of
GH on BMI and BP and had no effect on the atherogenic
index (TC/HDL-c).
Previously, we have shown that stimulated glucose levels
remained unchanged and fasting glucose levels rose slightly
during 6 yr of GH treatment. In addition, both fasting and
stimulated insulin levels increased significantly (11). It has
been reported that GH treatment increases serum insulin
levels in conditions such as GHD, Turner syndrome, and
renal diseases (23, 24). This has been attributed to a GH-
induced reduction of insulin sensitivity. Also, it has been
reported that postprandial glucose levels increase in indi-
viduals with a reduced insulin sensitivity (25).
Our present results show that after discontinuation of GH
treatment, fasting glucose and fasting insulin levels returned
to pretreatment levels. This indicates that the rise in glucose
and insulin levels were indeed a result of GH treatment. In
other patient groups, such as girls with Turner syndrome and
adolescents with and without GHD, similar results were
found after discontinuation of GH treatment (24, 26, 27).
Although fasting insulin levels at 6 months after discontin-
uation of GH treatment decreased to pretreatment levels,
stimulated insulin levels did not. The reason posttreatment-
stimulated insulin levels did not completely return to pre-
treatment levels might have various reasons. First, patients
were prepubertal at start and postpubertal after discontin-
uation of GH treatment. Euglycemic clamp tests or fre-
quently sampling iv glucose tolerance tests have shown that
insulin sensitivity in healthy children decreases during pu-
berty. Also, in these studies, postpubertal insulin sensitivity
did not return to prepubertal values (19, 28, 29). The higher
insulin levels were attributed to a reduced insulin sensitivity
in normal puberty and postpuberty (28). Thus, the reduced
insulin sensitivity, compared with baseline in our patients,
might be explained by their postpubertal stage. This is sup-
ported by the fact that posttreatment-stimulated insulin lev-
els were comparable with those of healthy adolescent peers.
Second, the BMI sd score increased during GH treatment.
Because a higher BMI is associated with higher insulin levels,
this might also explain the higher posttreatment-stimulated
insulin levels, compared with pretreatment levels (30, 31). In
accordance, we found that adolescents with high fasting and
stimulated insulin levels after discontinuation of GH treat-
ment had a significantly higher BMI sd score. Third, post-
treatment-stimulated insulin levels might be influenced by
the fact that these adolescents were born SGA. Significantly
higher insulin levels have been found after an oral glucose
load in young adults born SGA, compared with normal con-
trols (32, 33).
During the 6 yr of GH treatment, we found no differences
between the two GH dosage groups regarding fasting or
postprandial glucose and insulin levels. After discontinua-
tion of GH treatment, however, we observed that in the
higher GH-dosage group (group B), the decrease in the 30-
min ratio for insulin/glucose was significantly less profound
than in the lower GH-dosage group (group A). Because the
30-min ratio for insulin/glucose is an indicator for insulin
resistance, this finding might suggest that long-term treat-
ment with a higher GH dose of 6 IU/m2d ( 0.07 mg/kgd)
increases the degree of insulin resistance in children born
SGA even after discontinuation of GH treatment. Compared
with the control group, however, the mean 30-min ratio of
group B still falls into the normal range.
Because insulin resistance, either on its own or in combi-
nation with -cell dysfunction, causes IGT, we evaluated the
number of children in our group with IGT. We found that
after 6 yr of GH treatment, 1 of 27 children (4%) had IGT, and
at 6 months after discontinuation of GH treatment, IGT was
present in 3 of 29 children (10%). This result might be ex-
plained by the fact that puberty induces higher 120-min
glucose levels (28, 29). The predisposition for insulin resis-
tance and IGT in this group of adolescents born SGA, how-
ever, might also be responsible. Several studies found evi-
dence for insulin resistance in untreated short children born
SGA (34, 35). Also, being born with a LBW is associated with
IGT and DM type 2 (3, 36). On the other hand, mean glucose
levels at 6 months after discontinuation of GH decreased to
pretreatment levels, individual HbA1c levels never exceeded
the normal range, and none of the children developed DM
type 1 or 2.
Systolic and diastolic BP did not change after discontin-
uation of GH treatment. Another study evaluating the effect
of discontinuation of GH in adolescents with GHD showed
similar results (37). It has been reported that children and
TABLE 2. Serum lipid levels
Group A Group B Control group
TC (mmol/liter)
Pre-GH 4.9 (0.7) 4.6 (0.8)
6 yr GH 4.1 (0.5) 3.8 (0.6)
Post-GH 4.1 (0.5) 4.0 (0.7) 4.6 (0.8)
LDL-c (mmol/liter)
Pre-GH 2.9 (0.5) 2.7 (0.9)
6 yr GH 2.4 (0.5) 2.0 (0.7)
Post-GH 2.5 (0.5) 2.3 (0.7) 2.8 (0.7)
HDL-c (mmol/liter)
Pre-GH 1.5 (0.3) 1.4 (0.2)
6 yr GH 1.1 (0.2) 1.0 (0.2)
Post-GH 1.1 (0.2) 1.1 (0.4) 1.3 (0.3)
Atherogenic indexa
(TC/HDL-c)
3.0 (2.0–4.5) 3.0 (1.3–6.7) 3.7 (2.3–6.1)
Data expressed as mean (SD).
a Geometric mean (95% range).
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young adults born with a LBW had a significantly higher
systolic BP (38–41). In some studies this relationship was also
found when LBW was corrected for gestational age (41), but
in others it was not (32, 42). We reported, previously, that
before start of GH treatment, children born SGA had a sig-
nificantly higher systolic BP than reference values, which
decreased to normal during GH treatment (11). Our present
study shows that after discontinuation of GH treatment,
systolic BP was not different to age- and sex-matched ref-
erence values, whereas diastolic BP was even significantly
lower than reference values. These results contrast with data
of untreated subjects born SGA and might reflect a positive
influence of GH on blood pressure in this patient group.
During GH treatment serum TC, LDL-c, and HDL-c levels
decreased. Discontinuation of GH treatment resulted in a
slight increase in both LDL-c and HDL-c levels and no
change in total cholesterol levels. Previous reports have
shown that discontinuation of GH treatment in adolescents
with GHD resulted in either no effect on serum lipids (43) or
an increase in TC and LDL-c levels, without change in HDL-c
levels (37, 44). The increase in both LDL-c and HDL-c in our
children might also be an age effect (45, 46). We found that
the atherogenic index after discontinuation of GH treatment
was comparable with a control group of similar age. The lack
of difference in serum lipid levels between the two GH dos-
age groups suggests that the changes in lipid levels were not
related to GH treatment.
After discontinuation of GH treatment, we found a pos-
itive correlation among the atherogenic index, BMI sd score,
systolic and diastolic BP sd score, and fasting insulin level.
This might suggest that in some adolescents born SGA, a
clustering of risk factors for cardiovascular disease, as de-
scribed by Barker (4), is already present. A recent epidemi-
ological study, however, reported that an increased risk for
hypertension was mostly present in overweight young SGA
adults (47). Therefore, a possible strategy to prevent an in-
creased risk for cardiovascular disease in subjects born SGA
might be to prevent overweight.
In conclusion, in children born SGA, the GH-induced in-
sulin insensitivity disappeared after discontinuation of GH,
even after long-term GH treatment. Furthermore, the bene-
ficial effect of GH on BP was not changed by discontinuation
of GH. Although most children had normal serum lipid
levels, we did find a clustering of risk factors for cardiovas-
cular disease, which may point to their predisposition.
Whether long-term GH treatment will contribute to longev-
ity, however, remains to be investigated.
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